Q-omics provides the consensus-scored SHANK1 profile across patient tissues and cancer cell-line models. SHANK1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SHANK1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, SHANK1 RNA expression shows 17,950 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, HNSC, and GBM as cancer lineages where SHANK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHANK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHANK1 survival associations across molecular data types. SHANK1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHANK1 RNA expression–survival associations across cancer types. High SHANK1 expression shows unfavorable associations in BLCA, LUSC and THCA, but favorable associations in UVM, KICH and LAML. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SHANK1 RNA expression.
This table summarizes SHANK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SHANK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHANK1 shows higher tumor expression in HNSC, COAD, LUAD, KIRP, BRCA and LUSC. The HNSC box plot shows higher SHANK1 RNA expression in tumor versus normal tissue (log2 FC = +0.434, t-test p < 0.001).
This table shows molecular features associated with SHANK1 in patient tissues and cancer cell lines. In patient samples, SHANK1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SHANK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
